outlook driven compel pipelin
solid execut margin flow
updat chart solid cours growth margin
manag extend organ growth target margin
improv goal bp per year organ growth
remain rang beyond driven larg above-
bsx structur heart portfolio
support check watchman earli feedback launch
lotu tavr system pleas see recent note hr
tvt made minor revis sale ep project
remain high end growth goal
in-lin manag oper spend target
reiter outperform rate target
impress collect growth driver converg
much posit reaction bsx investor day updat center around
structur heart tavr watchman endoscopi spyglass single-
use scope addit compani neuromodul portfolio continu
drive share build momentum db afib busi
posit acceler take share new ablat
cathet launch intern
above-averag organ growth margin expans management continu
effect deliv impress organ growth continu improv
op margin commit exceed time
valuat target price base ebitda multipl
ebitda bil risk product delay failur progress lrp
goal potenti new litig regulatory/qu issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
mike mahoney chairman ceo provid open remark day outlin
enter new high-growth segment
mr mahoney laid bsx key strateg goal includ strengthen categori
leadership expand high growth adjac drive ww expans mr
mahoney also provid organ growth compound-annual-growth-rate in-lin
goal provid januari compani also reiter adjust oper margin
guidanc y/i double-digit y/i earn growth
also plan drive growth portfolio diversif includ increas
mix high-growth market compound-annual-growth-rate
period compani expect lower exposur low-growth market
compound-annual-growth-rate revenu mix moder growth market
compound-annual-growth-rate expect declin slightli total sale
compani estim expand high-growth market
approach bil size tabl highlight compani key high-
growth market growth driver
db parkinson diseas tremor
heartlog heart failur alert featur set reson platform help drive high singl digit growth high voltag market
brennan execut vice presid chief offic offic provid
financi overview compani mr brennan overview includ key financi metric
goal organ revenu cabr bp annual op
margin improv double-digit ep growth growth compound-annual-growth-rate
figur financi outlook vs cse consensu
compani also expect gm reach gm
improv expect driven reduct product cost annual
standard cost reduct optim compani plant network improv
portfolio mix sg expect driven optim global
facil improv effici distribut custom servic leverag commerci
sale market function busi process streamlin manag set goal
 spend look beyond manag expect
improv gross margin oper leverag drive oper margin
long term
manag set target bil bil driven
primarili work capit initi compani expect use
strateg object compar cash flow avail strateg invest
manag also plan repay bil debt next
month post btg close target leverag end
charl martineau pm univers toronto chang model
made minor revis sale ep project
beyond result manag commentari long-term outlook provid today
figur chang model
compani medsurg busi consist endoscopi urolog pelvic health
medsurg busi repres bil sale total sale
urolog pelvic health aim bil revenu
david pierc execut vice presid medsurg meghan scanlon vice presid
commerci gener manag urolog pelvic health provid overview
bsx urolog pelvic health busi divis repres bil sale
sale cc
aim bil sale
signific market opportun drive growth
shift minim invas procedur
compani estim urolog pelvic health market bil growth
driven demograph diseas preval diabet obes cardiovascular
diseas manag expect market grow compound-annual-growth-rate driven
increas demand less invas treatment expand patient access
market compris stone diseas bil men health mil women
figur urolog pelvic health drive multipl growth market
popul ww
affect kidney stone
men age
affect benign prostat
men ww affect
women ww affect
urinari incontin
men diagnos
men
increas risk kidney stone
prostat cancer
experi moder serv
ovarian cancer case
late stage often fatal due
lack reliabl diagnost
estim bil market grow bil anoth bil
key adjac overact bladder spaceoar gel prostat cancer
radiat treatment purchas part augmenix acquisit
total see urolog pelvic health market grow bil
figur urolog pelvic health market reach bil compound-annual-growth-rate
 tria stent soft firm
market leader bil stone diseas market manag highlight
lithovu digit flexibl ureteroscop deliv detail high-resolut digit
imag high-qual visual minim invas endoscop procedur
diagnos treat stone lithovu use procedur sinc launch
global center result pull-through compani stone
mil prostat health market grow compani see
signific opportun spaceoar gel prostat cancer radiat treatment
spaceoar acquir augmenix deal inject creat
addit space rectum prostat prostat cancer radiotherapi
reduc rectal radiat dose associ side effect compani
expect spaceoar address mil market expect sale mil
mil last year futur compani expect address new market
hydrogel includ pancrea breast thyroid gynecolog compani
also highlight rezum non-invas therapi system treat benign prostat
hyperplasia bph bph also call prostat gland enlarg common condit
men get older enlarg prostat gland caus urinari symptom
block flow urin bladder well bladder urinari tract kidney
problem compani see mil bph market driven increas
physician educ patient awar
compani estim mil prosthet urolog market grow
market leader prosthet urolog share offer comprehens
product portfolio context men age moder complet
erectil dysfunct mil men ww form male incontin
final bil women health market compani see meaning expans
opportun adjac market ovarian cancer mil high-risk
symptomat patient overact bladder mil market mil patient
endoscopi target bil revenu
art butcher senior vice presid presid endoscopi brian dunkin chief
medic offic endoscopi provid overview bsx endoscopi busi
divis repres bil sale sale cc
target bil sale
leadership larg grow market
expand high-growth adjac
charl martineau pm univers toronto compani estim bil endoscopi market grow compound-annual-growth-rate
market continu shift toward minim invas endoscop procedur
market compris infect prevent bil pancreaticobiliari diseas
bil gastrointestin cancer bil gastrointestin bleed mil
lead caus cancer
death pancreat
cancer-rel
mortal rate upper
lower gi bleed
failur rate tow
import step
everi minut someon
 die lung cancer
compani estim market reach bil repres
compound-annual-growth-rate driven expans high-growth adjac high-growth
adjac repres bil bil compani expect
high-growth adjac rise bil total market
figur high-growth adjac repres market
charl martineau pm univers toronto tabl highlight key growth driver market expans bsx
figur endoscopi market set grow bil
bil pancreaticobiliari diseas market manag emphas benefit
spyglass ds direct visual context spyglass first single-
use singl oper digit cholangioscop use direct visual diagnost
evalu simultan therapeut intervent bile duct date
patient countri treat spyglass compani place
consol compani also work next-gen spyglass devic
spyglass ds ii offer increas resolut featur broader portfolio
solut pancreatic/biliari procedur estim spyglass consum
util doubl last three year compani also
plan launch spyglass discov single-us choledochoscop design surgic
duct explor procedur pancreaticobiliari system manag
estim laparoscop cholecystectomi gallbladd remov
perform year repres mil market opportun
penetr manag also highlight axio stent eu guid
translumin therapi current indic axio includ pancreat fluid collect
pseudocyst drainag walled-off necrosi biliari tract obstruct gallbladd
bile duct drainag eu target mil market addit indic
explor includ metabol diseas benign gi structur malign gastric
outlet obstruct manag estim addit indic would open
bil market futur
faster grow new adjac manag highlight variou market
opportun ahead endolumin surgeri driven less invas endoscop
altern surgic resect cancer endolumin surgeri plan offer
surgeon train educ shift open surgeri laparoscop surgeri case
flexibl endoscopi context mil new gi cancer case year
new cancer case compani estim infect prevent
mil ww market opportun mil gi endoscopi perform year
 bsx infect prevent portfolio help mitig risk cross- contamin
also enhanc safeti patient healthcar provid manag also provid
updat single-us scope market respect exalt-d compani single-us
duodenoscop duodenum uppermost segment small intestin
stomach manag see bil market opportun compani submit
applic fda april expect launch exalt-d
end compani also laid single-us therapeut imag portfolio
expect target bil market pleas see note ddw take-away
initi coverag comprehens overview exalt-d bsx
launch
visual examin bile duct
expect launch end
expect launch
surgic duct explor procedur pancreaticobiliari system
use see insid airway lung
compani rhythm neuro busi consist rhythm manag
electrophysiolog neuromodul rhythm neuro busi repres
bil revenu sale cc
flat lsd -ve
tabl highlight key compon bil rhythm manag
market compris icm electrophysiolog
flat lsd neg
 db next gen
rhythm manag broad portfolio address larg market
fitzgerald execut vice presid presid rhythm manag ken
stein chief medic offic rhythm manag provid overview bsx rhythm
manag busi divis repres bil sale sale
cc
differenti heartlog
compani estim rhythm manag market bil
declin lsd flat bil market split high-voltag bil low-
voltag bil compani highlight reson platform heartlog
fda approv heart failur alert system multisens studi heartlog
prove success detect heart failur event advanc provid physician
week advanc notic potenti heart failur event compani also
provid updat clinic trial manage-hf trial current enrol
manage-hf ii random trial evalu clinic outcom heart failur event
mortal well econom impact expect first patient enrol
preempt-hf investig associ heartlog
readmiss also enrol patient compani also touch emblem s-icd
ww implant term modular system
compani expect start enrol
cardiac monitor compani view key adjac
manag outlin plan insert cardiac monitor icm compani
expect launch lux-dx insert cardiac monitor lux-dx
provid advanc detect predict alert streamlin workflow long-term
arrhythmia monitor next-gen lux-dx featur chronic monitor platform
new sensor capabl unlock adjac diseas state
electrophysiolog portfolio mix expand higher-growth segment
fitzgerald execut vice presid presid rhythm manag ken
stein chief medic offic rhythm manag also provid overview bsx
electrophysiolog busi divis repres mil sale
sale cc
new adjac drive futur growth
diversifi map navig cathet portfolio
compani estim ww ep market bil grow ldd ep market
compris ep lsd growth advanc map navig mid-to-high
teen growth singl shot mid-to-high teen growth
market advanc map navig compar howev
compani expect rise along contribut singl
shot technolog grow mid-to-high teen compar lsd
growth ep bsx ep portfolio expand higher growth segment
market new adjac compani expect ep growth acceler
figur ep market vs mix
compani highlight rhythmia map system use
case ww instal sinc system launch lumipoint map
softwar launch eu suit
autom tool streamlin interpret hd mapph data compani
alreadi sold lumipoint licens procedur
complet lumipoint intellanav mifi open-irrig oi ablat cathet
provid physician precis multidimension inform via mini-electrod
deliv highli local signal reflect exactli happen tip
cathet real-tim ablat procedur activ eu rhythmia
account case perform cathet expect launch japan
 pend fda approv final intellanav stablepoint
ep cathet includ directsens contact force-sens high-qual catheter-
tissu contact inform plan integr rhythmia eu launch
expect
term adjac manag provid overview polarx singl shot
cryoablat balloon singl shot cryoablat balloon maintain uniform size
balloon pressur phase therapi result greater balloon stabil also
featur customiz consol central key data result greater physician
control physician compani expect ce mark approv
launch schedul start manag also touch
lumin singl shot rf balloon multi-electrod irrig rf balloon
cathet system featur built-in camera design real-tim visual
ce mark approv start target
neuromodul under-penetrated high-growth market
maulik nanavati presid senior vice presid neuromodul milad girgi
vice presid global brain modul provid overview bsx neuromodul
busi divis repres mil sale sale cc
build comprehens pain portfolio
compani market share posit ww db share
posit bil neuromodul market highli under-penetrated expect
grow compound-annual-growth-rate driven patient therapi awar well
altern opiod market compris pain therapi rf ablat
vertiflex spinal stenosi brain modul movement disord
figur neuromodul fast-grow under-penetrated market
db movement
chronic neuropath
sever joint pain
moder lumbar
parkinson
opportun move
new technolog indic
pain therapi compani focus build comprehens portfolio
address full pain continuum across neuropath pain joint pain moder lumbar
recent vertiflex acquisit provid minim invas treatment option
mil non-surg symptomat moder lumbar spinal stenosi patient
advanc compani categori leadership beyond rf addit
vertiflex also expect result strong call point overlap given primari user
implant year final follow-up patient demonstr
patient treat superion system experienc clinic success least
two three questionnair measur symptom sever physic function patient
satisfact patient satisfi treatment compani expect
vertiflex sale reach mil context complet acquisit
privately-held vertiflex june mil up-front cash addit payment
conting commerci mileston next three year vertiflex develop
commerci superion indirect decompress minimally-invas devic
use improv physic function reduc pain patient lumbar spinal stenosi
respect wavewrit manag provid updat combo rct
prospect multicent rct demonstr valu multipl modal combin
mechan use spectra wavewrit initi data expect year
brain modul manag highlight larg opportun parkinson
popul remain under-penetrated manag estim mil
patient parkinson mil diagnos treat mil diagnos
treat patient around elig db actual receiv implant
data intrepid rct prospect double-blind sham-control
multicent rct bsx vercis db demonstr improv
motor function sustain year clinic studi associ bsx db
busi includ direct db prospect rct evalu therapeut advantag
cartesia direct lead vercis db direct system well db
registri global registri compil real world evid commerci avail
compani cardiovascular busi consist intervent cardiolog
peripher intervent cv busi bsx largest segment repres
bil revenu sale cc
-avvigo guidanc
 avvigo guidanc system
intervent cardiolog focu structur heart
kevin balling execut vice presid global presid intervent cardiolog
ian meredith execut vice presid global chief medic offic shawn
mccarthi vice presid gener manag structur heart valv provid
overview bsx ic busi divis repres bil sale
sale cc
innov
diversif strengthen categori leadership
intervent cardiolog encompass combin bil market includ rel
stabl slower-grow coronari therapi market bil faster-grow
structur heart market bil manag expect combin ic market grow
compound-annual-growth-rate driven primarili dd sh growth off-set rel flat growth
coronari therapi manag expect sh market reach bil total
sale core coronari therapi market project remain roughli
unchang growth driver sh market includ tavr laac mitral cep
figur sh market expect grow bil
mix ic revenu shift toward growth segment
compani seen ic revenu mix shift significantli
greater contribut structur heart go forward manag expect structur
heart repres ic sale stent account quarter
revenu
figur bsx ic revenu mix shift
manag highlight differenti aspect structur heart busi
includ lotu edg acur neo tavr sentinel cep milliped tmvr
tavr uniqu posit dual-valv portfolio lotu edg acur
address broad array patient need control launch lotu edg
underway full launch expect compani also enrol patient
repris iv studi intermediate-risk patient includ bicuspid cohort
approv expect compani also work next-gen lotu valv
mantra clinic trial expect initi follow lotu
mantra system initi clinic trial trial acur
present enrol ce mark expect beyond compani touch
acur prime expand size matrix fda approv expect
ng acur initi clinic trial manag also see signific market
opportun sentinel cerebr embol protect devic use
procedur adopt account use tavr
manag project mitral replac repair market reach bil ww
repair repres major market way background
compani enter acquisit option agreement privately-held milliped earli
develop iri transcathet annuloplasti ring system treatment
sever mitral regurgit iri deliv via transcatheter-transsept deliveri
system use stand-alon devic combin
technolog patient sever mr
manag provid updat watchman set expect exceed
cumul treat patient end patient june
watchman avail center compani receiv ce mark
next-gen watchman flx march product limit launch
june date center adopt flx success implant
compani target full commerci launch summer manag also laid
key driver clinic trial drive market expans watchman market
opportun estim mil expect rise bil result
penetr high-ble risk popul compani expect
market could grow bil result penetr low-to-moderate-ble risk
popul repres broader bleed risk popul
figur watchman clinic pipelin drive market expans
penetr low-to-moderate-ble risk
doac evalu broader bleed risk
penetr high-ble risk
coronari therapi repres bil ww market
revenu ou market revenu complex pci
compani current run activ clinic trial plan launch new
product annual combin invest new product solut
expect strengthen complex pci busi help maintain growth
jeff mirviss senior vice presid presid peripher intervent catherin
intervent provid overview bsx pi busi divis repres
bil sale sale cc
larg under-penetrated diseas state unmet need
categori leadership strategi portfolio strengthen btg acquisit
ww expans critic long-term growth
market leader bil pi market manag project grow
compound-annual-growth-rate market broken arteri diseas bil
growth venou diseas bil growth intervent oncolog
bil growth highlight key attribut market tabl
figur pi compris larg attract growth market
suffer pad
case dvt annual
diagnos liver cancer
 europ
year global
patient suffer
lower limb amput
 europ annual
peopl dvt
develop post-thrombot
caus death
annual breast cancer
lowest surviv rate
cancer
manag review detail key benefit propos btg acquisit
provid compani exposur bil adjac market
strengthen bsx categori leadership strategi across multipl diseas state
arteri diseas venou diseas intervent oncolog term background
compani announc acquisit btg plc novemb bil
deal expect close manag estim
accret bsx adjust ep target mil synergi
year three synergi accret assumpt in-lin manag initi
commentari guidanc context includ btg acquisit
model project beyond
bsx venou diseas portfolio manag touch key growth driver
well expans opportun propos combin btg compani
plan complet deep venou portfolio includ venou stent
mechan thrombectomi ivu imag cathet high-pressur balloon
result bil opportun eko endovascular system
ultrason devic help dissolv blood clot sentri bio-convert vena cava
filter expect result mil market opportun final varithena
inject microfoam treatment varicos vein also address mil market
opportun
intervent oncolog also number key growth driver expans
opportun come year compani see signific opportun
global expans btg
microspher two clinic trial underway target new indic primari liver
cancer stop-hcc metastat colorect cancer epoch manag also
believ theraspher provid opportun expand cancer
lung btg galil cryoablat system use treat patient liver kidney
cancer also repres growth driver mil market opportun
term bsx drug elut devic portfolio compani underlin benefit
eluvia control releas polymer-bas design context eluvia launch
 japan expect launch china
respect ranger dcb manag target commerci launch
see combin de dcb opportun rang bil
final compani expect global expans critic contributor long-term
growth busi context btg sale ou compar
bsx pi sale grew dd manag believ leverag bsx
ou expertis repres signific opportun btg expand sale ou
compani expect apac fastest grow region pi becom second
largest region behind
em china overview
june chang vice presid manag director greater china provid overview
bsx emerg market busi repres signific growth opportun
compani context em sale account total revenu grew
compani see complex pci pi oncolog watchman key growth
driver watchman implant patient china
compani train physician procedur
manag estim em grow compound-annual-growth-rate china
med-tech market reach bil bil driven
continu expans product portfolio broaden commerci
demograph increas patient access
charl martineau pm univers toronto compani mention price
